Alessandra Murabito M.S.
Alessandra Murabito received her Master Degree in Molecular Biotechnology in 2017 and she is currently a Ph.D. student in Biomedical Sciences and Oncology at the University of Torino (Italy). She joined the laboratory of Prof. Emilio Hirsch, a leader expert in PI3K signaling, when she was a bachelor student and she mainly focused her research on the characterization of a PI3KÎ³ mimetic peptide as a bronchodilator and anti-inflammatory drug in respiratory diseases. Under the guidance of Prof. Alessandra Ghigo, she started her Ph.D which is currently focused on the role of PI3KÎ³ in epithelial cells and the use of the PI3KÎ³ mimetic peptide for the treatment of cystic fibrosis. The data she obtained so far were considered robust enough by the European Medicinal Agency (EMA) to grant to the PI3KÎ³ mimetic peptide the Orphan Drug Designation on February 16th 2017 (number EU/3/17/1859). Alessandra Murabito already attended several international meetings and workshop, including the North American Cystic Fibrosis Conference (NACFC) in Indianapolis 2017, the European Cystic Fibrosis Society (ECFS) Basic Science Conference in Loutraki 2018, and the workshop 'Hands-on workshop- Epithelial Systems: Physiology and Pathophysiology' organized by the ECFS in Lisbon 2017, which provided her the opportunity to meet European and US leaders in cystic fibrosis research. She was also awarded a travel grant from the Italian Cystic Fibrosis Research Foundation for the 15th ECFS Basic Science Conference in Loutraki.